Phaseline

Targets › HEXB

HEXB (Beta-hexosaminidase subunit beta): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Metabolic and endocrine, Neurology; next expected readout Jan 2027.

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides. The isozyme B does not hydrolyze each of these substrates, however hydrolyzes efficiently neutral oligosaccharide. (UniProt, P07686)

Open in Phaseline: the race on HEXB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peter Ljubenkov, MDVerdiperstat
Hexosaminidase B (HEXB) inhibitor
HEXBPhase 1Semantic DementiaJan 2027
Dr. Anupam SehgalTSHA-101
AAV9 viral vector containing HEXA and HEXB genes
HEXA, HEXBPhase 1Infantile GM2 Gangliosidosis (Disorder)Mar 2027

Conditions

Infantile GM2 Gangliosidosis (Disorder) (1) Semantic Dementia (1)

Modalities

protein or peptide (1), small molecule (1)

Companies

Dr. Anupam Sehgal (1) Peter Ljubenkov, MD (1)

Related targets

HEXA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.